Convergen Suzhou Pharmaceutical Co. Ltd.
PrivateLast Round
Seed
Aug 31, 2026
Total Funding Raised
$25M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Convergen Suzhou Pharmaceutical Co. Ltd. operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Seed round in August 2026.
Convergen Suzhou Pharmaceutical Co. Ltd. is a biopharmaceutical company that develops targeted protein degradation therapies for neurodegenerative diseases and other conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Convergen Suzhou Pharmaceutical Co. Ltd. Comparables
Compare Convergen Suzhou Pharmaceutical Co. Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TRIMTECH Therapeutics | 87% | |
| Degron Therapeutics | 84% | |
| GluBio Therapeutics | 81% |
For institutional investors. Book with your work email.
Convergen Suzhou Pharmaceutical Co. Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Aug 31, 2026 | ||||
| Seed | Dec 8, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Convergen Suzhou Pharmaceutical Co. Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Seed |
| MPC | Seed |
| Lilly Asia Ventures | Seed |
| Qiming Venture Partners | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 31, 2026
$15M round led by MPC
- Dec 8, 2025
$10M round led by Qiming Venture Partners
For institutional investors. Book with your work email.
Convergen Suzhou Pharmaceutical Co. Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Convergen Suzhou Pharmaceutical Co. Ltd.'s valuation, stock price, and market status.
Is Convergen Suzhou Pharmaceutical Co. Ltd. a public or private company?
Convergen Suzhou Pharmaceutical Co. Ltd. is a private company.
What is the current stock price of Convergen Suzhou Pharmaceutical Co. Ltd.?
Convergen Suzhou Pharmaceutical Co. Ltd. is a private company, so its shares have no public market price. Caplight tracks Convergen Suzhou Pharmaceutical Co. Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Convergen Suzhou Pharmaceutical Co. Ltd. worth (valuation)?
Valuation information for Convergen Suzhou Pharmaceutical Co. Ltd. is not publicly available.
Can I buy Convergen Suzhou Pharmaceutical Co. Ltd. stock?
Convergen Suzhou Pharmaceutical Co. Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Convergen Suzhou Pharmaceutical Co. Ltd.'s last funding round?
Convergen Suzhou Pharmaceutical Co. Ltd.'s most recent funding round was Seed on August 31, 2026.
Who are the main investors in Convergen Suzhou Pharmaceutical Co. Ltd.?
Key investors in Convergen Suzhou Pharmaceutical Co. Ltd. include MPC, Qiming Venture Partners.
Will Convergen Suzhou Pharmaceutical Co. Ltd. IPO soon?
No public IPO plans have been announced for Convergen Suzhou Pharmaceutical Co. Ltd..
How can I track Convergen Suzhou Pharmaceutical Co. Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Convergen Suzhou Pharmaceutical Co. Ltd.'s shares on secondary markets.